BVF PARTNERS L P/IL Insider Trading $NBIX NEUROCRINE BIOSCIENCES INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for BVF PARTNERS L P/IL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is 10% Owner in LIGAND PHARMACEUTICALS INC ($LGND) and 10% Owner in AVIGEN INC \DE ($AVGN) and 10% Owner in NEUROCRINE BIOSCIENCES INC ($NBIX) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in CURIS INC ($CRIS) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in EPIRUS Biopharmaceuticals, Inc. ($CRXX).
BVF PARTNERS L P/IL in NEUROCRINE BIOSCIENCES INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of BVF PARTNERS L P/IL: 10% Owner
Holdings: 5,946,547 shares
Current Value: $259,269,449
Latest Transaction: Jan 26 2009
$NBIX Market Capitalization: $3.81B
$NBIX Previous Close: $43.60
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of BVF PARTNERS L P/IL in NEUROCRINE BIOSCIENCES INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARQL, AVGN, CRIS, DVAX, CRXX, LGND, NBIX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 6,000 | 18,586 | 5,946,547 | 5.9 M to 5.9 M (+0.10 %) |
| Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 2,000 | 6,195 | 5,940,547 | 5.9 M to 5.9 M (+0.03 %) |
| Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 1,000 | 3,098 | 5,938,547 | 5.9 M to 5.9 M (+0.02 %) |
| Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 4,000 | 12,400 | 5,937,547 | 5.9 M to 5.9 M (+0.07 %) |
| Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 1,000 | 3,100 | 5,933,547 | 5.9 M to 5.9 M (+0.02 %) |
| Jan 26 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.10 | 1,900 | 5,890 | 5,932,547 | 5.9 M to 5.9 M (+0.03 %) |
| Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.06 | 15,000 | 45,891 | 5,930,647 | 5.9 M to 5.9 M (+0.25 %) |
| Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.06 | 4,000 | 12,238 | 5,915,647 | 5.9 M to 5.9 M (+0.07 %) |
| Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.06 | 6,200 | 18,968 | 5,911,647 | 5.9 M to 5.9 M (+0.10 %) |
| Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.08 | 45,000 | 138,681 | 5,905,447 | 5.9 M to 5.9 M (+0.77 %) |
| Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.08 | 12,000 | 36,982 | 5,860,447 | 5.8 M to 5.9 M (+0.21 %) |
| Jan 22 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.08 | 18,000 | 55,472 | 5,848,447 | 5.8 M to 5.8 M (+0.31 %) |
| Jan 20 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.05 | 4,000 | 12,209 | 5,830,447 | 5.8 M to 5.8 M (+0.07 %) |
| Jan 20 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.05 | 1,000 | 3,052 | 5,826,447 | 5.8 M to 5.8 M (+0.02 %) |
| Jan 20 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.05 | 2,400 | 7,325 | 5,825,447 | 5.8 M to 5.8 M (+0.04 %) |
| Jan 02 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.80 | 7,000 | 19,600 | 5,823,047 | 5.8 M to 5.8 M (+0.12 %) |
| Jan 02 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.80 | 2,000 | 5,600 | 5,816,047 | 5.8 M to 5.8 M (+0.03 %) |
| Jan 02 2009 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.80 | 1,600 | 4,480 | 5,814,047 | 5.8 M to 5.8 M (+0.03 %) |
| Dec 03 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.35 | 59,000 | 138,402 | 5,812,447 | 5.8 M to 5.8 M (+1.03 %) |
| Dec 03 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.35 | 16,000 | 37,533 | 5,753,447 | 5.7 M to 5.8 M (+0.28 %) |
| Dec 03 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.35 | 24,400 | 57,238 | 5,737,447 | 5.7 M to 5.7 M (+0.43 %) |
| Nov 26 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.45 | 32,000 | 78,387 | 5,713,047 | 5.7 M to 5.7 M (+0.56 %) |
| Nov 26 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.45 | 9,000 | 22,046 | 5,681,047 | 5.7 M to 5.7 M (+0.16 %) |
| Nov 26 2008 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.45 | 13,400 | 32,825 | 5,672,047 | 5.7 M to 5.7 M (+0.24 %) |
Page: 1